Pneumocystis Jiroveci Pneumonia Clinical Trials

Find Pneumocystis Jiroveci Pneumonia Clinical Trials Near You

Phase I/II Safety lead-in Randomized Blind Placebo-controlled Clinical Trial: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia in Adjunction of Conventional Systemic Antifungal Therapy

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a GO / NO GO decision towards a phase III trial of nebulized caspofungin in those patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male and female ≥18 years

• Medical management of Pneumocystis pneumonia based on :

‣ Microbiological diagnosis of Pneumocystis pneumonia

⁃ Respiratory support (oxygen therapy or ventilatory assistance)

⁃ Systemic co-trimoxazole therapy or systemic second-line anti-Pneumocystis salvage therapy (switch to another anti-Pneumocystis drug is possible, but should be notified) (initiated within 48 hours or less before enrolment)

• Person affiliated to a French social security system or equivalent

• Written informed consent obtained from the participant or, if the patient is not able to give consent from representative (trusted person, family member) or if the delay in obtaining the consent is assumed not compatible with the enrollment requirements, a temporary approval can be obtained from the investigator. In all cases, the patient's written informed consent will have to be obtained as soon as possible.

Locations
Other Locations
France
CHU Orléans
RECRUITING
Orléans
CHRU Tours
RECRUITING
Tours
CHU Tours
NOT_YET_RECRUITING
Tours
Contact Information
Primary
Guillaume DESOUBEAUX, Prof
guillaume.desoubeaux@univ-tours.fr
+33(0)2 34 37 89 26
Backup
Stephan EHRMANN, Prof
stephanehrmann@gmail.com
+33(0)6 71 10 33 02
Time Frame
Start Date: 2025-12-02
Estimated Completion Date: 2028-12
Participants
Target number of participants: 100
Treatments
Experimental: Part 2 - randomized study (group 1)
Conventional systemic antifungal treatment (systemic co-trimoxazole or systemic second line anti-Pneumocystis salvage therapy) + aerosols of echinocandin (50 mg caspofungin) during one to seven days (according to the regimen retained from the results of part 1 from day-1 to d-7) using vibrating mesh nebulization device
Placebo_comparator: Part 2 - randomized study (group 2)
Control group: (in part 2 only) Conventional systemic antifungal treatment (systemic co-trimoxazole or systemic second-line anti-Pneumocystis salvage therapy) + aerosols of placebo (0.9% saline in a volume equivalent to the experimental group) during one to seven days (according to the regimen retained from part 1 results) using vibrating mesh nebulization device
Experimental: Part 1 - open study
open-label non-randomized group, with ascending scheme regarding the dose and rhythm of administration over one week, depending on the tolerance, and closely monitored in ICU to ensure that caspofungin is well tolerated via the inhaled route, and to provide data supporting the proposed administration scheme for part 2.~* the first two patients (included one by one) will receive two aerosols (5 mg) during the first week, four days apart on d-1 and d-5 (level 1);~* the third and fourth will receive two aerosols (15 mg) during the first week, four days apart on d-1 and d-5 (level 2);~* the fifth and sixth will receive two aerosols (50 mg) during the first week, four days apart on d-1 and d-5 (level 3);~* the seventh and eighth patients will receive four aerosols (50 mg) two days apart during one week, at d-1, then d-3, d-5 and d-7 (level 4);~* the last two patients will have daily aerosols during the first week, from d-1 to d-7 (level 5)
Sponsors
Collaborators: University Hospital, Montpellier, Amiens University Hospital, Hospices Civils de Lyon, Nantes University Hospital, Centre Hospitalier Universitaire Dijon, University Hospital, Brest, Poitiers University Hospital, University Hospital, Limoges, Hôpital Necker-Enfants Malades, Centre Hospitalier Universitaire de Besancon, Tours university, University Hospital, Angers, Institut National de la Santé Et de la Recherche Médicale, France, University Hospital, Bordeaux, Centre Hospitalier Universitaire de Nice, Hospital Avicenne, Wako Diagnostics, Rennes University Hospital, University Hospital, Lille, Reims University hospital, Henri Mondor University Hospital, Cape Cod Incorporated, Pitié-Salpêtrière Hospital, Hopital Foch, Ohre Pharma, University Hospital, Grenoble, Aerogen
Leads: University Hospital, Tours

This content was sourced from clinicaltrials.gov